Table 1 The characteristics of studies included in the NMA.

From: The effectiveness of optimal exercise-based strategy for patients with hip fracture: a systematic review and Bayesian network meta-analysis

Study, year	Participants (exercise vs control)					Interventions		Outcomes
Study, year	Type	Sample size	Age (EG)(\({\overline{\text{x}}}\) ± s)	Age (CG)(\({\overline{\text{x}}}\) ± s)	Gender (Female/male)	Duration (week)	Region	Outcomes
Sherrington et al., 1997	WBE	21 vs 21	80.00 ± 8.10	77.10 ± 8.20	8/13 vs 1/20	4	Australia	①
Hauer et al., 2002	RE	15 vs 13	81.70 ± 7.60	80.80 ± 7.00	NR	12	Germany	①②③④
Sherrington et al., 2003	WBE	41 vs 39	81.00 ± 7.00	81.10 ± 8.30	14/27 vs 12/27	2	Australia	①②③
Binderet al., 2004	RE	46 vs 44	80.00 ± 7.00	81.00 ± 8.00	13/33 vs 10/34	24	USA	①②③④
Suetta et al., 2004	RE	13 vs 12	69.00	68.00	7/6 vs 7/5	12	Denmark	①②
Sherrington et al., 2004	WBE	40 vs 40	80.10 ± 7.50	77.20 ± 8.90	10/30 vs 6/34	4	Australia	①②③
Mangione et al., 2005	AE vs RE	12 vs 11vs10	79.80 ± 5.60/77.90 ± 7.90	77.80 ± 7.30	3/9/4 vs 2/8/7	12	USA	①③
Mard et al., 2008	MSE	23 vs 20	74.00 ± 6.00	74.00 ± 7.00	8/16 vs 6/16	12	Finland	①
Mendelsohn et al., 2008	AE	10 vs 10	80.30 ± 7.40	81.10 ± 7.20	3/7 vs 3/7	4	USA	①②④
Portegijs et al., 2008	RE	23 vs 20	73.80 ± 6.60	74.10 ± 7.20	NR	12	Finland	①②
Mangione et al., 2010	RE	14 vs 12	79.60 ± 5.90	82.00 ± 6.00	2/12 vs 3/9	10	USA	①③
Kui et al., 2011	WBE	78 vs 74	71.80 ± 3.70	72.30 ± 3.70	30/48 vs 23/51	12	China	④
Yan et al., 2012	BE	20 vs 20	62.70 ± 6.30	61.34 ± 5.20	7/13 vs 9/11	24	China	③
Singh et al., 2012	RE	62 vs 62	80.10 ± 10.10	78.40 ± 9.00	19/43 vs 20/42	48	Australia	③
Sylliaas et al., 2012	RE	48 vs 47	82.40 ± 6.50	82.20 ± 5.10	9/39 vs 10/38	12	Norway	①②③
Morishima et al., 2014	AE	14 vs 14	60.30 ± 7.40	59.90 ± 5.40	0/14 vs 0/14	12	Japan	①
van Ooijen et al., 2016	AE	24 vs 23	82.90 ± 6.50	83.30 ± 8.00	8/16 vs 2/21	6	Netherlands	①③
Zhao et al., 2016	AE	60 vs 60	70.69 ± 8.76	70.15 ± 8.62	31/29 vs 32/28	12	China	③④
Xing et al., 2016	AE	50 vs 50	70.69 ± 8.76	70.15 ± 8.62	24/26 vs 24/26	12	China	③④
Zhang et al., 2017	MSE	30 vs 30	67.43 ± 2.81	68.27 ± 3.38	18/12 vs 16/14	2	China	③④
Xu et al., 2017	BE	35 vs 35	63.43 ± 7.20	64.20 ± 8.48	21/14 vs 20/15	24	China	②④
Monticone et al., 2018	RE	26 vs 26	77.20 ± 6.60	77.70 ± 7.50	7/19 vs 8/18	3	Italy	②③④
Wang et al., 2019	RE	53 vs 53	67.20 ± 2.10	66.10 ± 2.50	22/31 vs 21/32	12	China	③④
Kang et al., 2019	AE	34 vs 34	57.19 ± 10.08	55.71 ± 10.91	21/13 vs 20/14	48	China	③④
Wu et al., 2019	AE	50 vs 50	71.64 ± 5.59	71.42 ± 7.20	16/34 vs 17/33	72	China	③④
Dong et al., 2019	AE	46 vs 46	60.34 ± 2.19	60.78 ± 2.23	38/8 vs 37/9	12	China	③④
Stasi et al., 2019	AE	48 vs 48	77.50 ± 4.00	77.50 ± 4.50	12/36 vs 12/36	12	Greece	①
Cai et al., 2020	MSE	49 vs 49	66.53 ± 5.71	65.71 ± 6.32	19/30 vs 20/29	12	China	①③④
Xu et al., 2020	BE	42 vs 41	67.26 ± 3.29	67.58 ± 3.61	25/17 vs 23/18	24	China	②④
Qin et al., 2020	RE	43 vs 37	67.77 ± 3.22	68.34 ± 3.05	22/21 vs 18/19	12	China	③④
Oh et al., 2020	RE	19 vs 19	76.94 ± 9.43	81.15 ± 4.90	6/13 vs 6/13	1.5	Korea	②③④
Kim et al., 2020	AE	17 vs 17	52.82 ± 5.96	51.82 ± 5.91	13/4 vs 13/4	4	Korea	④
Wang et al., 2020	WBE	41 vs 41	51.50 ± 1.40	49.50 ± 1.80	25/16 vs 27/14	12	China	③④
Chi et al., 2020	WBE	38 vs 38	69.83 ± 4.12	70.15 ± 3.82	23/15 vs 24/14	12	China	③④
Sun et al., 2020	MSE	47 vs 43	68.73 ± 6.92	68.07 ± 7.01	25/22 vs 22/21	16	China	③④
Li et al., 2020	MSE	40 vs 40	64.77 ± 8.21	64.65 ± 8.65	21/19 vs 23/17	12	China	③④
Xu et al., 2021	RE	49 vs 49	72.34 ± 6.23	73.18 ± 6.82	29/20 vs 26/23	8	China	③④
Liu et al., 2021	BE	63 vs 62	64.71 ± 5.19	63.85 ± 5.43	28/35 vs 27/35	24	China	②④
Guo et al., 2021	BE	33 vs 33	68.54 ± 3.01	68.56 ± 3.02	16/17 vs 15/18	4	China	②③④
Ding et al., 2021	AE	40 vs 40	69.87 ± 8.81	70.21 ± 8.60	22/18 vs 21/19	12	China	③④
Wang et al., 2021	AE	49 vs 49	70.63 ± 6.96	70.05 ± 6.52	35/14 vs 31/18	12	China	③④
Corna et al., 2021	WBE	20 vs 20	83.60 ± 6.70	85.70 ± 8.40	5/15 vs 5/15	3	Italy	④
Paulsson et al., 2021	WBE	11 vs 18	79.20 ± 9.00	81.30 ± 8.00	1/10 vs 3/15	8	Sweden	③④
Overgaard et al., 2022	MSE	50 vs 50	78.30 ± 7.90	75.70 ± 8.10	6/44 vs 13/37	12	Denmark	①②③
Yan et al., 2022	MSE	50 vs 50	68.87 ± 6.27	67.19 ± 6.87	27/23 vs 24/26	9	China	③④
Li et al., 2022	RE	20 vs 20	54.08 ± 2.73	52.18 ± 3.01	15/5 vs 12/8	4	China	③④

AE aerobic exercise, BE balance exercise, CG control group, EG experimental group, MSE muscle strength exercise, NR not reported, RE resistance exercise, WBE weight-bearing exercise; ①, walking capacity;②, balance ability;③, activity of daily living;④, hip function.

Back to article page

Table 1 The characteristics of studies included in the NMA.

Search

Quick links